Johnson & Johnson (JNJ.N)
93.77USD
4:00pm EDT
$0.27 (+0.29%)
$93.50
$94.35
$94.40
$93.71
3,839,382
2,814,985
$94.41
$66.86
About
Overall
| Beta: | 0.58 |
| Market Cap (Mil.): | $262,630.91 |
| Shares Outstanding (Mil.): | 2,808.89 |
| Dividend: | 0.66 |
| Yield (%): | 2.82 |
Financials
| JNJ.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.78 | 37.93 | 37.76 |
| EPS (TTM): | 4.50 | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
Energizer loses two battery accounts, will buy a J&J unit
- Energizer Holdings Inc said on Wednesday that two U.S. retailers planned to stop selling its batteries, adding pressure to its sagging sales.
FDA limits use of J&J's Nizoral antifungal drug on safety concerns
- The Food and Drug Administration said it would limit the use of Johnson & Johnson's antifungal medicine, Nizoral tablets, warning that it may cause severe liver injuries and adrenal gland problems, and lead to harmful drug interactions.
FDA limits use of J&J's Nizoral antifungal drug on safety concerns
July 26 - The U.S. Food and Drug Administration said it would limit the use of Johnson & Johnson's antifungal medicine, Nizoral tablets, warning that it may cause severe liver injuries and adrenal gland problems, and lead to harmful drug interactions.
S&P retreats after eight days of gains as Coca-Cola drags
NEW YORK - The S&P 500 snapped its eight-day winning streak on Tuesday after disappointing sales from Coca-Cola, while investors turned cautious on the day before the Federal Reserve chairman's congressional testimony. | Video
J&J results beat forecasts; Elan share sale helps
- Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings on strong demand for its prescription drugs and medical devices, but a big gain from the sale of a stake in Irish drugmaker Elan Corp skewed the results.
UPDATE 3-J&J results beat forecasts; Elan share sale helps
July 16 - Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings on strong demand for its prescription drugs and medical devices, but a big gain from the sale of a stake in Irish drugmaker Elan Corp skewed the results.
CORRECTED-UPDATE 1-J&J results beat expectations, as drugs, devices deliver
(Corrects third paragraph to show Elan gain is not a special item)
J&J results beat expectations, as drugs, devices deliver
July 16 - Johnson & Johnson reported higher-than-expected second-quarter earnings as strong sales of prescription drugs and medical devices more than offset anemic growth of its consumer products.
J&J in $1 billion deal to bolster prostate-cancer focus
- Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
UPDATE 2-J&J in $1 bln deal to bolster prostate-cancer focus
By Ransdell Pierson June 17 - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand. J&J on Monday said Aragon's lead product, called ARN-509, has potential to help patients whose prostate cancer has not yet spread to other parts of the body, as well as patient
Competitors
| Price | Change | |
|---|---|---|
| General Electric Company (GE.N) | $24.62 | +0.25 |
| The Procter & Gamble Company (PG.N) | $81.64 | +1.34 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Medtronic, Inc. (MDT.N) | $55.49 | +0.25 |
| Baxter International Inc. (BAX.N) | $72.20 | -0.84 |
| Stryker Corporation (SYK.N) | $71.22 | +0.76 |
| Boston Scientific Corporation (BSX.N) | $11.15 | +0.23 |
| Zimmer Holdings, Inc. (ZMH.N) | $84.47 | +0.99 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (JNJ). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

